Table 1 Studies utilizing BLT-humanized mice for evaluating HIV-therapeutics

Antiviral therapy

dCA

[45, 56]

EFdA

[57]

RAL

[45]

PD-1 mAb

[58]

PG16 bNAb

[59]

PGT121 bNAb

[60]

3TC, TDF

[61]

AZT, ddI, IDV

[52]

FTC, RPV, DTG

[46, 57]

FTC, TAF, EVG

[62]

FTC, TDF, DTG

[37, 46, 51, 53, 63]

FTC, TDF, RAL

[37, 46, 51, 63]

FTC, TDF, RAL, 3B3(Fv)-PE38 immunotoxin

[64]

FTC, TDF, RAL, IFNα14

[61, 65]

Pre-exposure prophylaxis (PrEP)

C5A peptide

[66]

Cc-griffithsin

[67]

CD4 AsiCs

[68]

CD4-expressing Lactobacillus acidophilus

[69]

CD4mc P-III-48

[70]

DTG-ultra LA

[71]

EFdA

[72]

G2-S16 PCD

[73]

IgA

[74]

MVC

[75]

RAL-LA

[76]

RPV-LA

[39, 77]

siCCR5 LFA-1 I-tsNP

[78]

TNV gel

[79,80,81]

VRC01 bNAb

[82]

FTC, TAF

[83]

FTC, TDF

[36, 43, 84, 85]

TAF, EVG

[86]

b12, VRC01, VRC07 G54W bNAbs

[87]

Latency-reversing agents (LRAs)

AZD5582

[88]

panobinostat

[89]

SUW133 (bryostatin analog)

[90]

Vaccines

PLGA-Gag microparticles

[49, 91]

Recombinant GP140∆683

[49, 91]

Proviral excision

saCas9/sgRNA

[92]

T cell engineering

CCR5 shRNA

[93, 94]

CD4 CAR

[95]

3TC, lamivudine; AsiCs, aptamer-siRNA chimeras; AZT, zidovudine; bNAb, broadly neutralizing antibody; CCR5, C–C chemokine receptor type 5; CAR, chimeric antigen receptor; CD4, cluster of differentiation 4; CD4mc, CD4 mimetic compound; Cc, Caulobacter crescentus recombinant expressing; dCA, didehydro-Cortistatin A; ddI, didanosine; DTG, dolutegravir; DTG-ultra LA, long acting dolutegravir; EFdA, 4′-ethynyl-2-fluoro-2′-deoxyadeno-sine; EVG, elvitegravir; FTC, emtricitabine; IDV, indinavir; IFNα14, interferon α suptype 14; IgA, immunoglobulin A; LFA-1 I-tsNP, lymphocyte function–associated antigen-1 integrin-targeted and stabilized nanoparticle; mAb, monoclonal antibody; MVC, maraviroc; PCD, polyanionic carbosilane dendrimers; PD-1, programmed cell death protein 1; PLGA, poly(lactic-co-glycolic) acid; RAL, raltegravir; RAL-LA, long-acting raltegravir; RPV, rilpivirine; RPV-LA, long acting rilpivirine; saCas9/sgRNA, Staphylococcus aureus CRISPR-associated protein 9/single-guide RNA; shRNA, short hairpin RNA; siCCR5, small interfering RNA CCR5; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; TNV; tenofovir